Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery-investigation using a candesartan change-over study

Annals of Thoracic and Cardiovascular Surgery

Volumn 17, Issue 5, 2011, Pages 487-493

  Sezai, Akira ^a   Soma, Masayoshi ^a   Hata, Mitsumasa ^a   Yoshitake, Isamu ^a   Unosawa, Satoshi ^a   Wakui, Shinji ^a   Shiono, Motomi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin; Hypertension; Renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; IMIDAZOLE DERIVATIVE; OLMESARTAN; RENIN; TETRAZOLE DERIVATIVE;

AGED; ANALYSIS OF VARIANCE; ARTERY; ARTICLE; BLOOD; CLINICAL TRIAL; COMPLIANCE (PHYSICAL); DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART SURGERY; HEMODYNAMICS; HUMAN; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TIME; TREATMENT OUTCOME;

AGED; ALDOSTERONE; ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ARTERIES; BENZIMIDAZOLES; CARDIAC SURGICAL PROCEDURES; COMPLIANCE; DRUG SUBSTITUTION; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80054882392     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: 10.5761/atcs.oa.11.01691     Document Type: Article

References (18)

1. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
2. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the HARM-Added trial. Lancet 2003; 362:767-71.
3. Dahlof B, Devereux R, Kjeldsen SE, et al. Cardiovascularmorbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
4. Resnick LM, Catanzaro, Sealey JE, et al. Acute vasculareffects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the reninaldsterone system. Am J Hypertens 2004; 17: 203-8.
5. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory lood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxormil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41-50.
6. Aoki A, Ogawa T, Sumino H, et al. Long-term effects of telmisartan on blood pressure, the renin-angiotensin- aldsterone system, and lipids in hypertensive patients. Heart Vessels 2010; 25: 195-202.
7. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nenpeptide Ang II receptor antagonist, on the renin-angiotensin-aldsterone system in hypertensive patients. Hypertension 1995; 25: 37-46.
8. Sato A, Saruta T. Aldsterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781-8.
9. Hirata Y, Taura Y, Taguchi T, et al. Aldsterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology 2006; 11: 462-6.
10. Yoneda T, Takeda A, Usukura M, et al. Aldsterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007; 20: 1329-33.
11. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-8.
12. Agata J, Ura N, Yoshida H, et al. Olmesartan in an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006; 29: 865-74.
13. Igase M, Strawn WB, Gallagher PE, et al. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol 2005; 289: H1013-9.
14. Yokoyama H, Averill DB, Brosnihan KB, et al. Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens 2005; 18: 922-9.
15. Tsutamoto T, Nishiyama K, Yamaji M, et al. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 2010; 33: 118-22.
16. Ichikawa S, Takayama Y. Long-term effects of olmesartan, an ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldsterone system in hypertensive patients. Hypertens Res 2001; 24: 641-6.
17. Furukawa T, Hatsuno T, Ueno Y, et al. Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil. Clin Drug Investig 2009; 29: 257-64.
18. Fliser DF, Buchholz K, Haller H, et al. Antiinflammatoryeffects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-7.